Emma Levine: Fighting Childhood Cancer with Larotrectinib

 

​​

Age: 14
Pleasant Valley, New York
A message from Jennifer Huber and Kevin Levine, Emma’s parents.

Our daughter Emma was diagnosed with undifferentiated soft tissue sarcoma in August 2016. By March 2018, we were preparing for the worst because chemotherapy was not keeping the cancer at bay. Then, on June 22, 2018, we got the call of a lifetime; genetic profiling of Emma’s tumor had revealed she was a candidate for a clinical trial testing a promising new treatment called larotrectinib (Vitrakvi). Within days, we had enrolled Emma in the clinical trial, and she began taking larotrectinib. It has been a miracle drug for her. As of July 31, 2019 her cancer is almost undetectable, and she is living the life of a typical teenager.

Emma’s diagnosis came in the summer after she finished fifth grade. She had been having abdominal pain, losing weight, and her Tourette syndrome symptoms had been intensifying for a few months, but none of the doctors we saw could figure out what was wrong.

At yet another visit to her pediatrician, Emma had an ultrasound. It revealed a 10-centimeter tumor on her right kidney. We went straight to the local children’s hospital, where a CT scan confirmed the devastating news: Emma had cancer. She was immediately admitted to the pediatric oncology ward, and our lives were forever changed.

Within days Emma had surgery. Because the tumor was intertwined with her kidney, her entire right kidney was removed along with the tumor.

Emma spent the rest of August in the hospital recovering from the surgery. During that time, we had an agonizing wait to find out exactly what type of cancer it was and what Emma’s treatment would be moving forward.

It turned out that the cancer was an undifferentiated soft tissue sarcoma and only in her kidney. Emma began the first of seven cycles of chemotherapy the day she was supposed to start middle school. This treatment, which Emma received alongside 26 doses of radiation to the abdomen, was brutal. Emma spent much of the next 5 months in the hospital. But at the end of it, the scans showed no evidence of cancer. She was in remission. We thought the worst was behind us and began to resume life.

Then, in November 2017, Emma’s routine check-up scan showed that the cancer had returned and this time was in Emma’s lungs. We were utterly devastated. She had stage IV cancer and the prognosis was grim.

We were advised to enjoy Christmas with Emma and then start chemotherapy in the New Year, which we did. She only managed three cycles of the chemotherapy, however, because the side effects were unbearable, and the treatment was not keeping the cancer at bay.

At this point, Emma was in emotional turmoil and we transitioned to palliative chemotherapy. This allowed Emma to be treated at home and improved her quality of life a little.

While we were meeting to discuss hospice intake, we never gave up hope. That is why we followed our local oncologists’ recommendation to have Emma’s tumor genetically profiled by researchers at Dana-Farber/Boston Children’s.

Several months later, our local oncologist called to tell us to go straight to Boston. The genetic profiling had shown that Emma’s cancer was driven by an NTRK fusion. This meant she was a candidate for a clinical trial testing an investigational treatment [larotrectinib] that was showing a lot of success against cancers caused by NTRK fusions.

Within a month of starting larotrectinib, Emma’s health began improving and her 1-month scans showed the tumors had shrunk by 50 percent. A month later, the tumors had shrunk even further.

The difference in Emma’s quality of life while taking larotrectinib and while taking chemotherapy is like night and day. Chemotherapy left Emma emaciated and weak. She could not go to school and was frequently in the hospital. Since starting larotrectinib, Emma has gained almost 30 pounds and she just enjoyed her eighth-grade dance after completing her first full year of middle school.

Emma will continue to take larotrectinib and to have regular check-up scans for many years, if not the remainder of her life.

Larotrectinib saved Emma’s life, and we are so grateful to our local oncologist and everyone at Dana-Farber/Boston Children’s, especially Dr. Janeway and Dr. DuBois. It has been a true collaboration, and we are very blessed to have such caring and dedicated people fighting in Emma’s corner with us.

Top of page

American Association for Cancer Research Foundation
The AACR Cancer Progress Report is published by the American Association for Cancer Research (AACR). The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration.

Requests for permission to reuse or reprint any part of the Cancer Progress Report should be sent to permissions@aacr.org.

© 2018 AACR | 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106
215-440-9300 | aacr@aacr.org

The American Association for Cancer Research (AACR) is a 501(c)(3) registered nonprofit organization (23-6251648).
Other AACR Sites
AACR Website
AACR Foundation Website
Cancer Today Magazine
AACR Blog: Cancer Research Catalyst

Follow the AACR


Follow the AACR Foundation